S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

REGENXBIO (RGNX) Stock Forecast, Price & News

+1.05 (+5.31%)
(As of 05/13/2022 06:55 PM ET)
Today's Range
50-Day Range
52-Week Range
443,700 shs
Average Volume
420,723 shs
Market Capitalization
$898.91 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.



REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$470.35 million
Cash Flow
$3.35 per share
Book Value
$15.99 per share


Net Income
$127.84 million
Pretax Margin




Free Float
Market Cap
$898.91 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.19 out of 5 stars

Medical Sector

264th out of 1,403 stocks

Biological Products, Except Diagnostic Industry

42nd out of 206 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions

Is REGENXBIO a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGENXBIO stock.
View analyst ratings for REGENXBIO
or view top-rated stocks.

Are investors shorting REGENXBIO?

REGENXBIO saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 3,660,000 shares, an increase of 20.8% from the April 15th total of 3,030,000 shares. Based on an average daily trading volume, of 414,700 shares, the days-to-cover ratio is currently 8.8 days. Currently, 10.1% of the shares of the stock are sold short.
View REGENXBIO's Short Interest

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for REGENXBIO

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Tuesday, March, 1st. The biotechnology company reported $6.67 earnings per share for the quarter, topping analysts' consensus estimates of $4.28 by $2.39. The biotechnology company earned $398.66 million during the quarter, compared to the consensus estimate of $255.76 million. REGENXBIO had a net margin of 21.38% and a trailing twelve-month return on equity of 17.92%. The company's quarterly revenue was up 1759.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.24) earnings per share.
View REGENXBIO's earnings history

What price target have analysts set for RGNX?

7 brokers have issued 12 month price targets for REGENXBIO's shares. Their forecasts range from $17.00 to $82.00. On average, they anticipate REGENXBIO's share price to reach $47.86 in the next twelve months. This suggests a possible upside of 129.6% from the stock's current price.
View analysts' price targets for REGENXBIO
or view top-rated stocks among Wall Street analysts.

Who are REGENXBIO's key executives?
REGENXBIO's management team includes the following people:
  • Mr. Kenneth T. Mills, Pres, CEO & Director (Age 47, Pay $1.72M)
  • Mr. Vittal K. Vasista, Exec. VP & Chief Financial Officer (Age 54, Pay $1.25M)
  • Mr. Curran M. Simpson M.S., Exec. VP and Chief Operations & Technology Officer (Age 60, Pay $924.95k)
  • Dr. Olivier Danos Ph.D., Exec. VP & Chief Scientific Officer (Age 64, Pay $842.08k)
  • Mr. Patrick J. Christmas II, J.D., Exec. VP & Chief Legal Officer (Age 51, Pay $1.11M)
  • Ms. Tricia Truehart, VP of Investor Relations & Corp. Communications
  • Mr. Andrew Yost, VP of Corp. Devel.
  • Ms. Shiva G. Fritsch, Chief People Officer
  • Dr. Laura A. Coruzzi J.D., Ph.D., Sr. VP of Intellectual Property (Age 69)
  • Mr. Ram Palanki, Sr. VP of Commercial Strategy & Operations
What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO CEO Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among REGENXBIO's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.28%), JPMorgan Chase & Co. (10.95%), Vanguard Group Inc. (9.44%), Dimensional Fund Advisors LP (1.81%), WS Management Lllp (1.10%) and Northern Trust Corp (0.96%). Company insiders that own REGENXBIO stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends for REGENXBIO

Which major investors are selling REGENXBIO stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Gyon Technologies Capital Management LP, Citigroup Inc., Mirae Asset Global Investments Co. Ltd., Connor Clark & Lunn Investment Management Ltd., SG Americas Securities LLC, Northern Trust Corp, and Metropolitan Life Insurance Co NY. Company insiders that have sold REGENXBIO company stock in the last year include Allan M Fox, Kenneth T Mills, Steve Pakola, and WR Stephens, Iii 2012 Trust.
View insider buying and selling activity for REGENXBIO
or view top insider-selling stocks.

Which major investors are buying REGENXBIO stock?

RGNX stock was acquired by a variety of institutional investors in the last quarter, including WS Management Lllp, Assenagon Asset Management S.A., American Century Companies Inc., Jennison Associates LLC, Dimensional Fund Advisors LP, Los Angeles Capital Management LLC, BlackRock Inc., and Russell Investments Group Ltd..
View insider buying and selling activity for REGENXBIO
or or view top insider-buying stocks.

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $20.84.

How much money does REGENXBIO make?

REGENXBIO has a market capitalization of $898.91 million and generates $470.35 million in revenue each year. The biotechnology company earns $127.84 million in net income (profit) each year or $2.15 on an earnings per share basis.

How many employees does REGENXBIO have?

REGENXBIO employs 372 workers across the globe.

What is REGENXBIO's official website?

The official website for REGENXBIO is www.regenxbio.com.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 552-8181 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.